| Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities T Grosser, S Fries, GA FitzGerald The Journal of clinical investigation 116 (1), 4-15, 2006 | 1372 | 2006 |
| Prostaglandin E2 regulates vertebrate haematopoietic stem cell homeostasis TE North, W Goessling, CR Walkley, C Lengerke, KR Kopani, AM Lord, ... Nature 447 (7147), 1007-1011, 2007 | 1336 | 2007 |
| Role of prostacyclin in the cardiovascular response to thromboxane A2 Y Cheng, SC Austin, B Rocca, BH Koller, TM Coffman, T Grosser, ... Science 296 (5567), 539-541, 2002 | 1113 | 2002 |
| Understanding multicellular function and disease with human tissue-specific networks CS Greene, A Krishnan, AK Wong, E Ricciotti, RA Zelaya, ... Nature genetics 47 (6), 569-576, 2015 | 1000 | 2015 |
| Prostanoids in health and disease EM Smyth, T Grosser, M Wang, Y Yu, GA FitzGerald Journal of lipid research 50, S423-S428, 2009 | 715 | 2009 |
| Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti‐Inflammatory Drugs KN Theken, CR Lee, L Gong, KE Caudle, CM Formea, A Gaedigk, ... Clinical Pharmacology & Therapeutics 108 (2), 191-200, 2020 | 385 | 2020 |
| Timing of expression of the core clock gene Bmal1 influences its effects on aging and survival. FGGA Yang G, Chen L, Grant GR, Paschos G, Song WL, Musiek ES, Lee V ... Sci Transl Med 8, 324, 2016 | 376 | 2016 |
| The clinical pharmacology of nonsteroidal antiinflammatory drugs and coxibs. T Grosser Applied pharmacokinetics & pharmacodynamics: Principles of therapeutic drug …, 2006 | 369* | 2006 |
| Antiinflammatory, antipyretic and analgesic agents T Grosser, EM Smyth, GA FitzGerald Goodman and Gilman’s the Pharmacological Basis of Therapeutics (12th Edition …, 2011 | 353* | 2011 |
| Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin T Grosser, S Fries, JA Lawson, SC Kapoor, GR Grant, GA FitzGerald Circulation 127 (3), 377-385, 2013 | 321 | 2013 |
| Celecoxib pathways: pharmacokinetics and pharmacodynamics L Gong, CF Thorn, MM Bertagnolli, T Grosser, RB Altman, TE Klein Pharmacogenetics and genomics 22 (4), 310-318, 2012 | 284 | 2012 |
| Emotion recollected in tranquility: lessons learned from the COX-2 saga T Grosser, Y Yu, GA FitzGerald Annual review of medicine 61 (1), 17-33, 2010 | 279 | 2010 |
| Developmental expression of functional cyclooxygenases in zebrafish T Grosser, S Yusuff, E Cheskis, MA Pack, GA FitzGerald Proceedings of the National Academy of Sciences 99 (12), 8418-8423, 2002 | 262 | 2002 |
| The cardiovascular pharmacology of nonsteroidal anti-inflammatory drugs T Grosser, E Ricciotti, GA FitzGerald Trends in pharmacological sciences 38 (8), 733-748, 2017 | 256 | 2017 |
| Deciphering the human platelet sheddome KP Fong, C Barry, AN Tran, EA Traxler, KM Wannemacher, HY Tang, ... Blood, The Journal of the American Society of Hematology 117 (1), e15-e26, 2011 | 203 | 2011 |
| Enteric coating and aspirin nonresponsiveness in patients with type 2 diabetes mellitus DL Bhatt, T Grosser, J Dong, D Logan, W Jeske, DJ Angiolillo, ... Journal of the American College of Cardiology 69 (6), 603-612, 2017 | 198 | 2017 |
| Bioinformatic analysis of circadian gene oscillation in mouse aorta RD Rudic, P McNamara, D Reilly, T Grosser, AM Curtis, TS Price, ... Circulation 112 (17), 2716-2724, 2005 | 186 | 2005 |
| Analysis of the zebrafish proteome during embryonic development MB Lucitt, TS Price, A Pizarro, W Wu, AK Yocum, C Seiler, MA Pack, ... Molecular & Cellular Proteomics 7 (5), 981-994, 2008 | 168 | 2008 |
| Prostanoids and inflammatory pain L Chen, G Yang, T Grosser Prostaglandins & other lipid mediators 104, 58-66, 2013 | 167 | 2013 |
| Marked interindividual variability in the response to selective inhibitors of cyclooxygenase-2 S Fries, T Grosser, TS Price, JA Lawson, S Kapoor, S DeMarco, ... Gastroenterology 130 (1), 55-64, 2006 | 164 | 2006 |
Garret A. FitzGeraldU. PennVerified email at upenn.edu
